Drug profile

The FDA adverse-event record for Anti-Inflammatory Injection (Unknown)

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Anti-Inflammatory Injection (Unknown). See the species affected, top reactions, and outcomes below.

12
adverse-event reports
8.3%
death-coded share
Dog
most-reported species
4
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
8.3%
Death Rate

Active Ingredients

Anti-Inflammatory Injection (Unknown)

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Dog 12

Most Affected Breeds

Shih Tzu 3
Spaniel - Cocker American 1
Terrier - Yorkshire 1
Chow Chow 1
Spaniel - Springer English 1
Retriever - Labrador 1
Poodle - Miniature 1
Crossbred Canine/dog 1
Saint Bernard Dog 1
Chihuahua 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 4
Diarrhoea 3
Seizure NOS 3
Agitation 3
Cough 2
Behavioural disorder NOS 2
Nystagmus 2
Staggering 2
Vestibular disorder NOS 2
High blood pressure 2
Elevated lactate 2
Falling 2

Outcome Breakdown

Recovered/Normal
5 (41.7%)
Recovered with Sequela
3 (25.0%)
Ongoing
2 (16.7%)
Died
1 (8.3%)
Outcome Unknown
1 (8.3%)

Anti-Inflammatory Injection (Unknown) Adverse Event Insights

12 reports name Anti-Inflammatory Injection (Unknown); 1 recorded a death outcome (8.3% of reported events, not a population-level mortality rate). Active ingredient: Anti-Inflammatory Injection (Unknown). Administration routes: Unknown, Subcutaneous, Parenteral.

By species: Dog (12 reports). By breed: Shih Tzu (3), Spaniel - Cocker American (1), Terrier - Yorkshire (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (4), Diarrhoea (3), Seizure NOS (3), Agitation (3). Outcome, 12 coded reports: Recovered/Normal leads at 41.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.